Patients with Inflammatory Bowel Disease (IBD) are at Increased Risk for Colorectal Cancer and Early Dysplasia

Overview

About this study

The purpose of the study is to:

Map and compare the neoplasia-associated epigenetic field in IBD-CRN, sporadic CRN and controls.
Measure sensitivity of DNA methylation for the detection of synchronous IBD-CRN as a complement or alternative to histologic diagnosis of dysplasia on random biopsies.
Measure the density and types of lymphocytes infiltrating IBD-CRN tumors, sporadic tumors and the epigenetic field.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Subject population: Patients with chronic colitis (ulcerative colitis or Crohn’s colitis) who have undergone surgery to treat medically refractory disease or disease complications, including advanced pre-cancer or cancer of the colorectum.

Inclusion Criteria:

Patients will be adults having surgery at Mayo Clinic with chronic inflammatory bowel disease of the colon.

Exclusion Criteria:

Pre-operative chemotherapy or radiation;

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator John Kisiel, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

John Kisiel, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials